Immune Tolerance Mediated by TIM-3,LAG-3 and BTLA and Their Reversion in Hematological Malignancies-Review
Shao-Hua CHEN; Xiang-Feng ZHA; Yang-Qiu LI.
Journal of Experimental Hematology
; (6): 1594-1597, 2016.
Artículo en Zh | WPRIM | ID: wpr-332645
Documentos relacionados
[Immune Tolerance Mediated by TIM-3,LAG-3 and BTLA and Their Reversion in Hematological Malignancies-Review].
Advances in cancer immunotherapies.
Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
The neglected brothers come of age: B cells and cancer.
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.
Dual regulation effect and mechanism of human myeloid-derived suppressor cells on anticolorectal cancer cells activity of Vγ9Vδ2 T cells.
Resistance Mechanisms to Anti-PD Cancer Immunotherapy.
B Cell Function in the Tumor Microenvironment.
Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
Cancer immunotherapy: T cells and neutrophils working together to attack cancers.